ClinicalTrials.gg
CompletedNCT04056169Updated Aug 16, 2019

Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome

A Phase 4 interventional study of high-dose rosuvastatin and low-dose rosuvastatin plus ezetimibe in Acute Coronary Syndrome and Carotid Atherosclerotic Plaque With Inflammation, sponsored by Yuhan Corporation. Completed at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-08-16.

Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jun 2017, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing rosuvastatin in Acute Coronary Syndrome — 2 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Acute Coronary Syndrome.

Enrollment
16th of 16
50 · median 193
Started
2017
with 1 other
Phase 4
9 of 16
1 open now
Registered
13th of 16
by date

Among the 16 studies testing rosuvastatin in Acute Coronary Syndrome, this one is the 16th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 4, and was the 13th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

2 of the 16 studies testing rosuvastatin in Acute Coronary Syndrome are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing rosuvastatin in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

Combination therapy of ezetimibe with a low-dose statin is occasionally used to avoid statin-related side effects in clinical practice among patients with atherosclerotic cardiovascular disease. This approach is equivalent to high-dose statin therapy to decrease LDL cholesterol level by >50%, allowing such patients to achieve LDL cholesterol target. However, it remains uncertain whether combination therapy with ezetimibe and low-dose statin verse high-dose statin monotherapy similarily suppress atherosclerotic plaque inflammation. This study is to compare high-dose rosuvastatin versus low-dose rosuvastatin plus ezetimibe on carotid plaque inflammation in patients with acute coronary syndrome using 18F-fluorodeoxyglucose (18FDG) positron emission tomography (PET) imaging.

03

Conditions studied

  • Acute Coronary Syndrome
  • Carotid Atherosclerotic Plaque With Inflammation

Keywords

  • rosuvastatin
  • ezetimibe/rosuvastatin
  • carotid plaque inflammation
  • fluorodeoxyglucose F18
  • positron emission tomography
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged ≥ 19 years
  2. acute coronary syndrome, carotid artery disease (diameter stenosis 20-50%), and at least one 18FDG uptake lesion in the carotid artery (target to background ratio (TBR) ≥ 1.6) by 18FDG PET/CT imaging
  3. written consent

Exclusion criteria

Exclusion Criteria:

  1. previous history of carotid endarterectomy or stenting
  2. schedule for cardiac or major surgery within the next 6 months
  3. statin or ezetimibe therapy in the past 4 weeks
  4. chronic disease needed to be treated with oral, intravenous, or intraarticular
  5. end-stage renal disease
  6. chronic liver disease
  7. history of cancers within the past 3 years
  8. pregnant, breast-feeding or
  9. expected within 2 years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Rosuvastatin

    rosuvastatin 20 mg once a day for 6 months

    Drug: high-dose rosuvastatin

  • Experimental
    ezetimibe/rosuvastatin

    ezetimibe/rosuvastatin 10/5 mg once a day for 6 months

    Drug: low-dose rosuvastatin plus ezetimibe

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change in most-diseased segment (MDS)-tissue blood ratio (TBR) of the index vessel

    Time frame: 6 months

Secondary outcomes

  1. Change in MDS TBR

    Time frame: 6 months

  2. Change in whole vessel TBR within the index vessel

    Time frame: 6 months

  3. Change in whole vessel TBR of the aorta

    Time frame: 6 months

  4. Change in total cholesterol

    Time frame: 6 months

  5. Change in triglyceride

    Time frame: 6 months

  6. Change in HDL-cholesterol

    Time frame: 6 months

  7. Change in LDL-cholesterol

    Time frame: 6 months

  8. Change in high sensitive C-reactive protein

    Time frame: 6 months

07

Study locations

2 sites
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jul 2019, 24 months.

Of 92 phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 14, 2019
StartActual
Jun 29, 2017
Primary completionActual
Jul 23, 2019
CompletionActual
Jul 23, 2019
Last update
Aug 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04056169
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Aug 14, 2019
Start date
Jun 29, 2017
Primary completion
Jul 23, 2019
Completion
Jul 23, 2019
Last update
Aug 16, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Ezetimibe

Start the discussion